Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus
Methodological detailsmodified RAND/UCLA Delphi methodology, two Delphi rounds, multidisciplinary European panel, 55 statements across 9 thematic areas, 9-point Likert scale; consensus predefined as ≥ 80% agreement
- Modified RAND/UCLA Delphi methodology
- Two Delphi rounds
- Multidisciplinary European panel
- 55 statements across 9 thematic areas, 9-point Likert scale; consensus predefined as ≥ 80% agreement
Recommendations
As issued by the authors
- consensus
Correct reversible triggers of AF
- consensus
Haemodynamic assessment before HR control
- consensus
Individualised cardioversion strategy
- consensus
Landiolol for HR control in selected septic shock patients with new-onset atrial fibrillation (NOAF) (high β₁-selectivity, rapid titratability)
- consensus
Start landiolol without bolus, at low doses gradually titrated, to an initial HR target below 110 bpm, guided by close haemodynamic and echocardiographic monitoring
- no consensus
Optimal duration of landiolol therapy
- no consensus
Use of landiolol in patients with severe ventricular dysfunction
Original publication
Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus. Crit Care. Published 7 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →